BEACON2 is a platform multi-arm multi-stage (MAMS) randomised phase I/phase II, open-label, international trial for participants with relapsed neuroblastoma.

This study aims to improve the outcome for patients with newly diagnosed high-risk neuroblastoma.

This study aims to collect information about the outcome of patients with neuroblastoma and spinal cord compression.